Rafael Fonseca, MD

Rafael Fonseca, MD, discusses factors for selecting a treatment in relapsed/refractory multiple myeloma.

Dr. Rafael Fonseca presents the primary results of the phase 3 AURIGA study, which demonstrates the significant improvement in MRD-negative conversion and progression-free survival with subcutaneous daratumumab plus lenalidomide versus lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma post-transplant, shared at the 2024 International Myeloma Society Annual Meeting.

Closing out their discussion on novel agents in multiple myeloma, expert panelists consider remaining unmet needs and future evolutions in the treatment paradigm.

Key opinion leaders consider the potential for CAR T-cell therapy in earlier lines of therapy for patients with multiple myeloma.

Expert perspectives on how to manage adverse events associated with CAR T-Cell therapy in patients with relapsed/refractory multiple myeloma.

Shared insight on clinical trial data behind the KarMMa trial of ide-cel, a CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

Shifting their focus to CAR T-cell therapies, expert hematologist-oncologists review data from the CARTITUDE-1 trial of cilta-cel and its subgroup analyses.

Focusing on recent clinical trial data, expert panelists take a broad look at how they might select and sequence bispecific antibody therapies in practice.

Shared insight on the adverse event profiles of novel bispecific antibody therapies, with specific focus on how CRS can be adequately managed by the health care team.

After reviewing other novel bispecific antibodies including talquetamab, cevostamab, and elranatamab in RRMM, panelists consider how these agents compare and might be selected for specific patients.

Shifting toward the practical use of bispecific antibody teclistamab in RRMM, experts consider appropriate patient selection and investigational combination strategies.

Focusing on relapsed/refractory MM, expert panelists review data from MajesTEC-1 and consider how bispecific antibodies are impacting the treatment paradigm.

Ajai Chari, MD provides an overview of treatment options in patients with multiple myeloma at first relapse and those with triple-refractory disease

Expert hematologist-oncologists home in on clinical trial data to consider which regimens are most appropriate for patients with transplant-ineligible NDMM.

An overview of the frontline treatment armamentarium for patients with transplant-ineligible multiple myeloma and review of the MAIA and SWOG-S0777 trials.

Before closing out their discussion on transplant-eligible NDMM, expert panelists consider the role of maintenance therapy following transplant.

Expert perspectives on the optimal duration of treatment in patients with transplant-eligible newly diagnosed multiple myeloma.

Comprehensive discussion on the assessment of response to frontline therapy for transplant-eligible multiple myeloma and the role of MRD negativity in assessing response.

Shared insight on clinical trial results from both the GRIFFIN and MASTER trials, and the key role of frontline quadruplet regimens in transplant-eligible NDMM.

Expert hematologist-oncologists open their discussion on NDMM management by reviewing frontline data from the recent DETERMINATION trial.

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

Rafael Fonseca, MD, weighs the risks and benefits of quadruplet regimens in patient with multiple myeloma.

Rafael Fonseca, MD, discusses key data in multiple myeloma.

Rafael Fonseca, MD, discusses the emergence of minimal residual disease in multiple myeloma.

Rafael Fonseca, MD, hematologist, Mayo Clinic, discusses the use of fluorescence in situ hybridization (FISH) in diagnosing patients with myeloma.

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discuses the recent FDA approval of daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

Rafael Fonseca, MD, professor of Medicine, Mayo Clinic, discusses some of the ongoing clinical trials that could be potentially practice changing for the treatment of patients with multiple myeloma.